Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
yttrium Y 90-edotreotide · 2 trials · 8 indications
| Name | Type | Description |
|---|---|---|
| yttrium Y 90-edotreotide | RADIATION | - |
DISEASE CHARACTERISTICS: Histologically confirmed small cell lung cancer Must have received one prior chemotherapy regimen and relapsed OR Diagnosis of metastatic breast cancer No more than two prior chemotherapy regimens for metastatic disease Measurable disease Prior radiotherapy to measurable les...
Top 20 of 92 competitors
Yttrium Y 90-edotreotide is an investigational radiopharmaceutical being studied for treating brain and central nervous system tumors and breast cancer. It has been evaluated in clinical trials for patients with refractory or recurrent cancers, including these indications.
Yttrium Y 90-edotreotide is being developed by Novartis AG, which trades under the ticker NVS. The company has sponsored clinical trials investigating this drug in oncology settings.
Yttrium Y 90-edotreotide is in Phase 1 clinical development. It remains investigational and has not been approved by regulatory authorities. One Phase 1 trial has been completed, along with a separate Phase 2 trial.
Yttrium Y 90-edotreotide has been studied in two completed trials: NCT00006368, a Phase 1 study in patients with refractory or recurrent cancer, and NCT00006370, a Phase 2 study in patients with refractory small cell lung cancer or metastatic breast cancer.
Yttrium Y 90-edotreotide is a radiopharmaceutical that delivers radioactive yttrium-90 to cancer cells. It is designed to target somatostatin receptors, which are often overexpressed on certain tumor types, allowing for targeted radiation therapy.